Trial to Evaluate CIS43LS in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Malaria
Interventions
DRUG

VRC-MALMAB0100-00-AB

VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum (P. falciparum) circumsporozoite protein and incorporates an LS mutation to increase product half-life in plasma.

OTHER

Plasmodium falciparum (P. falciparum) sporozoite challenge

Participants were exposed to bites on the forearm from Anopheles stephensi mosquitoes infected with P. falciparum (3D7 strain).

Trial Locations (2)

20814

VRC Clinic, NIH Clinical Center, Bethesda

21201-1595

University of Maryland Baltimore, Center for Vaccine Development, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04206332 - Trial to Evaluate CIS43LS in Healthy Adults | Biotech Hunter | Biotech Hunter